Zuyderland Medisch Centrum Stichting

Research site

The Netherlands Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands

38 trials recruiting
Idiopathic pulmonary fibrosis · Obesity · Arteriosclerosis
Adults and children

About Specializations

Zuyderland Medisch Centrum Stichting in Heerlen, The Netherlands specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Obesity, Arteriosclerosis, Atrial fibrillation, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Henri Dunantstraat 56419 PC HeerlenThe Netherlands

Open in maps ↗

Recruiting now: 38 trials
Conditions studied: 91

More sites in Heerlen The Netherlands

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

97 clinical trials

Small cell lung cancer+2

Recruiting

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

Study of BNT327 with etoposide and carboplatin compared to atezolizumab with etoposide and carboplatin for patients with untreated extensive-stage small-cell lung cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:BioNTech SE

Contact Research Centre

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Selatogrel
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational

The Netherlands

Participants:18–64 years · 65+ years

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Atrial fibrillation

Recruiting

Phase 3 Study of Etripamil Nasal Spray Compared with Placebo in Patients with Atrial Fibrillation and Rapid Ventricular Rate

Investigational

Phase 3 Study of Etripamil Nasal Spray Compared with Placebo in Patients with Atrial Fibrillation and Rapid Ventricular Rate

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Etripamil
Sponsor:Milestone Pharmaceuticals Inc.

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Asthma

Recruiting

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational

GB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Generate Biomedicines Inc.

Contact Research Centre

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Novo Nordisk A/S

Contact Research Centre

Triple negative breast cancer

Recruiting

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Rectal cancer

Recruiting

Testing a Drug Combination with Fluorouracil, Irinotecan, Oxaliplatin, and Folinic Acid Plus Radiation Therapy for Patients with Advanced Rectal Cancer

Registered drugNo placebo

Testing a Drug Combination with Fluorouracil, Irinotecan, Oxaliplatin, and Folinic Acid Plus Radiation Therapy for Patients with Advanced Rectal Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Catharina Ziekenhuis Stichting

Contact Research Centre

Ankylosing spondylitis

Recruiting

A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Investigational

A Study of Tulisokibart for Adults with Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tulisokibart
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Arteriosclerosis

Recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pelacarsen
Sponsor:Novartis Pharma AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites